IGROOVE: Optimal Frequency of Dance in People at Risk for Alzheimer's Disease

Sponsor
Wake Forest University Health Sciences (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05507905
Collaborator
(none)
160
1
4
56
2.9

Study Details

Study Description

Brief Summary

The purpose of this research study is to determine if physical activity (dancing) is important for maintaining and improving memory in older adults and, if so, how many times a week is necessary. If a participant is deemed qualified to participate, he/she will be placed into one of four groups and will attend 1, 2, or 3 group or music appreciation classes per week for 24 weeks. In addition to attending the group classes, participants will be asked to complete at least four study visits at Wake Forest Baptist Medical Center to complete various clinical assessments.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Music
  • Behavioral: Dance Classes
N/A

Detailed Description

IGROOVE is an individually randomized group treatment trial that is controlled and single-blind. It will enroll adults aged 65 years and older who are low-active, report a Cognitive Change Index score ≥16, do not meet criteria for mild cognitive impairment or dementia, are healthy enough to complete repeated graded exercise testing (GXT), and have no contraindications for Magnetic resonance imaging (MRI). Randomization will be assessed to ensure equal distribution across study arms for these sex and body mass index (BMI) and will be stratified if necessary. New participants will be rolled into the intervention every 6 weeks with the beginning of the new form. Data collection will take place at Atrium Wake Forest Baptist Health. Interventions will take place in community sites, such as local dance studios, community centers, community gyms or churches. All intervention sites selected will be handicap accessible, well-lit, have appropriate flooring for safe dance movement, and access to sturdy chairs without wheels or arms.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
IGROOVE will randomize 160 participants meeting enrollment criteria in a 1:1:1:1 fashion to attend a music appreciation class control or dance classes either 1x/week, 2x/week or 3x/week for 24 weeks.IGROOVE will randomize 160 participants meeting enrollment criteria in a 1:1:1:1 fashion to attend a music appreciation class control or dance classes either 1x/week, 2x/week or 3x/week for 24 weeks.
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Establishing the Optimal Frequency of Dance Movement for Neurocognitive and Physical Outcomes in People at Risk of Alzheimer's Disease
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2027
Anticipated Study Completion Date :
Jul 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dance 3 Times Weekly (3xD)

Participants in this arm will attend classes 3 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.

Behavioral: Dance Classes
Four Different dance forms taught for 6 weeks each

Experimental: Dance 2 Times Weekly (2xD)

Participants in this arm will attend classes 2 times a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.

Behavioral: Dance Classes
Four Different dance forms taught for 6 weeks each

Experimental: Dance 1 Time Weekly (1xD)

Participants in this arm will attend a class 1 time a week for 24 weeks. During the 24 weeks, four different dance forms will be practiced. Each dance form will be taught for 6 weeks.

Behavioral: Dance Classes
Four Different dance forms taught for 6 weeks each

Active Comparator: Music Appreciation Control (MAC)

In the MAC, the music associated with that dance form will be used as the subject for classes and will also change every 6 weeks.

Behavioral: Music
Music associated with dance forms in dance classes.

Outcome Measures

Primary Outcome Measures

  1. Peak Oxygen Consumption (VO2) [Baseline]

    Assessed with Graded Exercise Test (GXT) Peak oxygen consumption, a marker of cardiorespiratory fitness (ml/kg/min) Shows effect on Cardio Respiratory Function.

  2. Peak Oxygen Consumption (VO2) [Month 1]

    Assessed with Graded Exercise Test (GXT) Peak oxygen consumption, a marker of cardiorespiratory fitness (ml/kg/min) Shows effect on Cardio Respiratory Function.

  3. Peak Oxygen Consumption (VO2) [Month 3]

    Assessed with Graded Exercise Test (GXT) Peak oxygen consumption, a marker of cardiorespiratory fitness (ml/kg/min) Shows effect on Cardio Respiratory Function.

  4. Peak Oxygen Consumption (VO2) [Month 6]

    Assessed with Graded Exercise Test (GXT) Peak oxygen consumption, a marker of cardiorespiratory fitness (ml/kg/min) Shows effect on Cardio Respiratory Function.

  5. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [Baseline]

    Shows effect on Cognitive Function. Overall score from the RBANS; Average/Mild Impairment (standard scores of 70 or above), Moderate Impairment (standard scores from 55 to 69), and Severe Impairment (standard scores <54) Scores range from 40 to 160.

  6. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [Month 1]

    Shows effect on Cognitive Function. Overall score from the RBANS; Average/Mild Impairment (standard scores of 70 or above), Moderate Impairment (standard scores from 55 to 69), and Severe Impairment (standard scores <54) Scores range from 40 to 160.

  7. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [Month 3]

    Shows effect on Cognitive Function. Overall score from the RBANS; Average/Mild Impairment (standard scores of 70 or above), Moderate Impairment (standard scores from 55 to 69), and Severe Impairment (standard scores <54) Scores range from 40 to 160.

  8. Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) [Month 6]

    Shows effect on Cognitive Function. Overall score from the RBANS; Average/Mild Impairment (standard scores of 70 or above), Moderate Impairment (standard scores from 55 to 69), and Severe Impairment (standard scores <54) Scores range from 40 to 160.

Secondary Outcome Measures

  1. Class Attendance [Week 24]

    Percent attendance (number of classes attended divided by number of classes offered in that arm)

  2. Lifestyle Self-Efficacy [Weekly Up through Week 24]

    Questionnaire that shows perceived confidence to engage in sufficient physical activity through accumulation over extended periods of time. The scale has a range of scores from 0-90. A higher number on the score represents a higher self-efficacy for exercise.

Other Outcome Measures

  1. Expanded short physical performance battery (eSPPB) [Baseline, Month 1, Month 3, Month 6]

    The eSPPB is a brief test of global mobility function with excellent test-retest and inter-examiner reliability; is sensitive to change; is safe, and is a robust predictor of future physical disability and death. To avoid ceiling effects, investigators will use an expanded version (eSPPB) that increases the difficulty of the standing balance task by asking participants to hold postures for 30 instead of 10 seconds, adds a one-leg stand, and adds a narrow walk. The resulting score is normally distributed, continuous, and shows greater sensitivity to change. Dementia patients have lower scores on the SPPB so a favorable outcome for this outcome measure would be a significantly higher score post treatment. The eSPPB is scored as a continuous measure with a maximum score of 3.0 where 3 is the best possible outcome.

  2. Gait Variability [Baseline, Month 1, Month 3, Month 6]

    Assessed over 4m 3 times at usual pace and 3 times at fast pace using an instrumented mat (GAITRite System); it will provide data on the variability in these measures

  3. Postural Sway [Baseline, Month 1, Month 3, Month 6]

    Center of pressure (millimeter squared) collected using an Advanced Mechanical Technology Incorporated (AMTI) AccuSway biomechanics force platform.

  4. Timed Up and Go (TUG) [Baseline, Month 1, Month 3, Month 6]

    The Timed Up and Go test is used to assess a person's mobility and requires both static and dynamic balance. Time in seconds that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees.

  5. Overall physical activity [Baseline, Month 1, Month 3, and Month 6]

    Overall volumes of movement in minutes per day

  6. Dance Self-Efficacy [Baseline, Month 1, Month 3, Month 6]

    For dance arms only. Perceived confidence to engage in an individual's specific dance program over extended periods of time. Five items scored on a scale of 0-10. A total score will be generated by summing scores from all five items and dividing by 5, for a potential range of total scores from 0-10, where a higher score is better.

  7. Brief Psychological Needs Satisfaction and Frustration Scale (BPNSFS)--Satisfaction [Baseline, Month 1, Month 3, Month 6]

    The BPNSFS yields overall scores on two scales: satisfaction and frustration. An overall score for satisfaction (total possible = 60, higher score is better) will be calculated.

  8. Brief Psychological Needs Satisfaction and Frustration Scale (BPNSFS)--Frustration [Baseline, Month 1, Month 3, Month 6]

    The BPNSFS yields overall scores on two scales: satisfaction and frustration. . An overall score for frustration (total possible = 60, lower score is better) will be calculated.

  9. Magnetic Resonance Imaging (MRI)-Neuro imaging [Baseline, Month 6]

    Grey matter volume (cm3); voxelwise freewater calculated from neurite orientation dispersion and density imaging (NODDI) image; from functional MRI (fMRI) graph theory analysis, global efficiency and modular structure

  10. Average Heart Rate [Weekly up through Week 24]

    Collected with chest-worn strap (beats per minute)

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Cognitive Change Index score ≥16

  • Montreal Cognitive Assessment (MoCA) score ≥21

  • Cognitively normal

  • Low-active for past 6 months (<30 min, 3 days/week of exercise, including walking for exercise)

  • MRI compatible

  • Willing and able to complete exercise testing.

  • Has reliable transportation or is able to use transportation provided by the study.

  • English speaking (needed for group class participation)

Exclusion Criteria:
  • Unable or unwilling to attend intervention classes 1-3x/week

  • Current diagnosis of a major neurological disorder (Alzheimer's disease, Lewy body dementia, Frontotemporal dementia, Parkinson's disease, amyotrophic lateral sclerosis, etc.)

  • Unwilling or unable to provide consent for study participation.

  • Currently symptomatic or cortical stroke or stroke deemed exclusionary by the study physician. Reported or observed evidence of strokes on MRI will be reviewed on a case-by-case basis by the study physician to assess factors such as location, size, time since stroke, and residual symptoms.

  • Taking medication during the intervention times that could negatively influence safety

  • Current cancer treatment or other major medical problems that might independently affect cognition or movement or interfere with ability to attend intervention or study visits.

  • Chronic vertigo.

  • Enrolled in another interventional research study ≤3 months prior to beginning this study.

  • Hip fracture, hip or knee replacement, or spinal surgery in past 6 months.

  • Health contraindications for completing a graded exercise test and movement intervention, including uncontrolled hypertension (BP>200/110 mmHg), hypertriglyceridemia (TG>400 mg/dl), uncontrolled diabetes (HbA1c > 7.5), clinical evidence of anemia.

  • Self-reports regularly drinking > 14 alcoholic beverages a week or current illicit drug use.

  • Unable or unwilling to understand study procedures and comply with them for the duration of the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Wake Forest School of Medicine Winston-Salem North Carolina United States 27157

Sponsors and Collaborators

  • Wake Forest University Health Sciences

Investigators

  • Principal Investigator: Christina Hugenschmidt, PhD, Wake Forest University Health Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wake Forest University Health Sciences
ClinicalTrials.gov Identifier:
NCT05507905
Other Study ID Numbers:
  • IRB00086190
First Posted:
Aug 19, 2022
Last Update Posted:
Aug 19, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wake Forest University Health Sciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 19, 2022